MAAT INDEX

CLAIM #22955 · EMR (EMR) · 2025Q4 earnings call · Nov 5, 2025 · due Sep 30, 2026

Operations is expected to generate about $0.50 of incremental EPS in 2026 with approximately 80 basis points of margin expansion from positive price/cost and the continued benefit of synergy realization from AspenTech and Test & Measurement.

Michael Baughman · CFO

PENDING
graded after results covering Sep 30, 2026 are reported

How to check this claim

Look at: Incremental adjusted EPS contribution from operations, fiscal year 2026, and adjusted segment EBITDA margin expansion

It came true if: Operations-driven incremental EPS approximately $0.50 (0.45-0.55) and adjusted segment EBITDA margin expansion approximately 80 basis points (70-90 bps) year-over-year

Where: Company fiscal 2026 full-year earnings release and management commentary (Q4 FY2026 earnings call, adjusted EPS bridge and segment margin disclosures)

In context

reflects strong operational execution despite a softer sales growth quarter and a tough comparison to Q1 2025. We expect EPS contributions from operations of about $0.05 and nonoperating items of approximately $0.04, offsetting a $0.07 impact from the software contract renewal dynamic just discussed. As a reminder, Q1 2025 adjusted EPS of $1.38 included the benefit of several dynamics such as discretionary cost containment and favorable project closeouts in Control Systems & Software. It's also important to note that lower volume from renewals impacts Emerson's adjusted segment EBITDA margin by approximately 80 basis points in the quarter. For the full year, the renewal dynamic reduces adjusted EPS by approximately $0.15 and adjusted segment EBITDA margin by approximately 40 basis points. Operations is expected to generate about $0.50 of incremental EPS in 2026 with approximately 80 basis points of margin expansion from positive price/cost and the continued benefit of synergy realization from AspenTech and Test & Measurement. Please turn to Slide 13 for a few comments on cash flow and capital allocation in 2026. As mentioned earlier, we are expecting free cash flow of $3.5 billion to $3.6 billion in 2026, representing approximately 10% growth, which will come from higher earnings and working capital efficiency. During the portfolio transformation, our capital allocation was weighted towards M&A. Increasing the dividend has been a priority for the last 69 years, but the annual increases to dividend per share were minimal during the transformation. Now that the transformation is complete. In 2026, we plan to raise our full year dividend per share $0.11 or approximately 5%, which is a significant increase compared to prior years. This raise marks the beginning of our 70th consecutive year of increasing dividends

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2025Q4 earnings call.